Cytomegalovirus Diagnostics Market , 2012-2023

January 2018 | 211 pages | ID: C429AB0F2E1EN
Precision Business Insights (PBI)

Abstracts

Global Cytomegalovirus Diagnostics Market

Cytomegalovirus (CMV) infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and blood transfusion are the other way for the transmission for the disease.

Cytomegalovirus diagnostics market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, initiatives taken by key market players for the diagnosis of CMV infection are propelling the growth of CMV diagnostics market. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to propel growth of CMV diagnostics market. Lack of awareness and price sensitivity are the few factors hampering the growth of CMV diagnostics market.

The global cytomegalovirus Diagnostics market is classified on the basis of test, application, end-user, and geography.

Based on test, the global cytomegalovirus Diagnostics market is segmented into the following:

• Serology
• Cell culture
• Antigenemia assay
• Polymerase Chain Reaction Amplification
• Immunohistochemistry
• Nucleic acid sequence-based amplification (NASBA)
• Hybrid capture assay

Based on application, the global cytomegalovirus diagnostics market is segmented into the following

• Retinitis
• Pneumonia
• Gastrointestinal Ulcers
• Encephalitis
• Others (Mouth Ulcers, Pharyngitis, etc.)

Based on the end-user, the global cytomegalovirus diagnostics market is segmented into the following:

• Hospitals
• Diagnostic Centers
• Others

Rise in diagnosis of CMV cases propelling the growth of global cytomegalovirus diagnosis market. According to Public Health Agency of Canada, 40%-100% of global population are having CMV antibody in the body. Patients with HIV and who has undergone organ transplantation, new-borns, and premature infants are having high risk of CMV infection. As per Centres for Disease Control and Prevention 1 per 150 infants are born with CMV infection in U.S. but only 1 in 5 infants are infected with CMV are having long term health issues.

Geographically cytomegalovirus diagnostics market is segmented as Latin America, North America, Asia- Pacific, Europe and The Middle East & Africa. Growing awareness about the herpes virus and rise in diagnosis of CMV cases in the developed regions such as Europe and North America are dominating the market. Initiatives taken by government about the awareness of the CMV disease, rise in healthcare expenditure and increase in disposable income are the few factors propelling market growth in Asia-Pacific region.

In Jun 2017, Abbott received U.S. FDA approval for Real-time CMV molecular test, the only cytomegalovirus test which is available commercially which amplifies two selective regions of CMV genome

In May 2016, Roche received U.S. FDA approval for its cytomegalovirus (CMV) test used in recipients of hematopoietic stem cells transplantation

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CYTOMEGALOVIRUS DIAGNOSTICS MARKET INTRODUCTION

2.1. Global Cytomegalovirus Diagnostics Market – Taxonomy
2.2. Global Cytomegalovirus Diagnostics Market –Definitions
  2.2.1. Test Type
  2.2.2. End User

3. GLOBAL CYTOMEGALOVIRUS DIAGNOSTICS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cytomegalovirus Diagnostics Market Dynamic Factors - Impact Analysis

4. GLOBAL CYTOMEGALOVIRUS DIAGNOSTICS MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis

5. GLOBAL CYTOMEGALOVIRUS DIAGNOSTICS MARKET, BY TEST TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. Serology
  5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Cell Culture
  5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Antigenemia Assay
  5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Polymerase Chain Reaction Amplification
  5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Immunohistochemistry
  5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Nucleic Acid Sequence-based Amplification (NASBA)
  5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis
5.7. Hybrid Capture Assay
  5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.7.3. Market Opportunity Analysis

6. GLOBAL CYTOMEGALOVIRUS DIAGNOSTICS MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Retinitis
  6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Pneumonia
  6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Gastroenteritis
  6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Encephalitis
  6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Others (Mouth Ulcers, Pharyngitis, etc.)
  6.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis

7. GLOBAL CYTOMEGALOVIRUS DIAGNOSTICS MARKET, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. Hospitals
  7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Diagnostic Centers
  7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Others
  7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL CYTOMEGALOVIRUS DIAGNOSTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. North America
  8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Cytomegalovirus Diagnostics Market - Opportunity Analysis Index, By Test Type, By Application, By End User, and Region, 2017 – 2023

9. NORTH AMERICA CYTOMEGALOVIRUS DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

9.1. Test Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Serology
  9.1.2. Cell culture
  9.1.3. Antigenemia assay
  9.1.4. Polymerase Chain Reaction Amplification
  9.1.5. Immunohistochemistry
  9.1.6. Nucleic acid sequence-based amplification (NASBA)
  9.1.7. Hybrid capture assay
9.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.2.1. Retinitis
  9.2.2. Pneumonia
  9.2.3. Gastrointestinal Ulcers
  9.2.4. Encephalitis
  9.2.5. Others (Mouth Ulcers, Pharyngitis, etc.)
9.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.3.1. Hospitals
  9.3.2. Diagnostic Centers
  9.3.3. Others
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Cytomegalovirus Diagnostics Market - Opportunity Analysis Index, By Test Type, By Application, By End User, and Country, 2017 – 2023
9.6. North America Cytomegalovirus Diagnostics Market Dynamics – Trends

10. EUROPE CYTOMEGALOVIRUS DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Test Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Serology
  10.1.2. Cell culture
  10.1.3. Antigenemia assay
  10.1.4. Polymerase Chain Reaction Amplification
  10.1.5. Immunohistochemistry
  10.1.6. Nucleic acid sequence-based amplification (NASBA)
  10.1.7. Hybrid capture assay
10.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.2.1. Retinitis
  10.2.2. Pneumonia
  10.2.3. Gastrointestinal Ulcers
  10.2.4. Encephalitis
  10.2.5. Others (Mouth Ulcers, Pharyngitis, etc.)
10.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Hospitals
  10.3.2. Diagnostic Centers
  10.3.3. Others
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Cytomegalovirus Diagnostics Market - Opportunity Analysis Index, By Test Type, By Application, By End User, and Country, 2017 – 2023
10.6. Europe Cytomegalovirus Diagnostics Market Dynamics – Trends

11. ASIA-PACIFIC CYTOMEGALOVIRUS DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Test Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Serology
  11.1.2. Cell culture
  11.1.3. Antigenemia assay
  11.1.4. Polymerase Chain Reaction Amplification
  11.1.5. Immunohistochemistry
  11.1.6. Nucleic acid sequence-based amplification (NASBA)
  11.1.7. Hybrid capture assay
11.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.2.1. Retinitis
  11.2.2. Pneumonia
  11.2.3. Gastrointestinal Ulcers
  11.2.4. Encephalitis
  11.2.5. Others (Mouth Ulcers, Pharyngitis, etc.)
11.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.3.1. Hospitals
  11.3.2. Diagnostic Centers
  11.3.3. Others
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Cytomegalovirus Diagnostics Market - Opportunity Analysis Index, By Test Type, By Application, By End User, and Country, 2017 – 2023
11.6. Asia-Pacific Cytomegalovirus Diagnostics Market Dynamics – Trends

12. LATIN AMERICA CYTOMEGALOVIRUS DIAGNOSTICS MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Test Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Serology
  12.1.2. Cell culture
  12.1.3. Antigenemia assay
  12.1.4. Polymerase Chain Reaction Amplification
  12.1.5. Immunohistochemistry
  12.1.6. Nucleic acid sequence-based amplification (NASBA)
  12.1.7. Hybrid capture assay
12.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.2.1. Retinitis
  12.2.2. Pneumonia
  12.2.3. Gastrointestinal Ulcers
  12.2.4. Encephalitis
  12.2.5. Others (Mouth Ulcers, Pharyngitis, etc.)
12.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Hospitals
  12.3.2. Diagnostic Centers
  12.3.3. Others
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Cytomegalovirus Diagnostics Market - Opportunity Analysis Index, By Test Type, By Application, By End User, and Country, 2017 – 2023
12.6. Latin America Cytomegalovirus Diagnostics Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA CYTOMEGALOVIRUS DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

13.1. Test Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Serology
  13.1.2. Cell culture
  13.1.3. Antigenemia assay
  13.1.4. Polymerase Chain Reaction Amplification
  13.1.5. Immunohistochemistry
  13.1.6. Nucleic acid sequence-based amplification (NASBA)
  13.1.7. Hybrid capture assay
13.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.2.1. Retinitis
  13.2.2. Pneumonia
  13.2.3. Gastrointestinal Ulcers
  13.2.4. Encephalitis
  13.2.5. Others (Mouth Ulcers, Pharyngitis, etc.)
13.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.3.1. Hospitals
  13.3.2. Diagnostic Centers
  13.3.3. Others
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Cytomegalovirus Diagnostics Market - Opportunity Analysis Index, By Test Type, By Application, By End User, and Country, 2017 – 2023
13.6. MEA Cytomegalovirus Diagnostics Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Cell Medical Ltd. (U.K.)
  14.2.2. Merck & Co. Inc. (U.S.)
  14.2.3. Chimerix, Inc. (U.S.)
  14.2.4. Abbott Laboratories (U.S.)
  14.2.5. Affymetrix, Inc. (U.S.)
  14.2.6. Becton, Dickinson and Company (U.S.)
  14.2.7. Bio-Rad Laboratories, Inc. (U.S.)
  14.2.8. F. Hoffmann-La Roche Ltd.( Switzerland)
  14.2.9. Johnson and Johnson Services Inc.,(U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS